Skip to main content

Hanging Drop based automated and parallelized cell technology platform for production and testing

Objective

Cell-based screenings are today a necessary tool for all types of clinical development and/or market approval of new drugs and chemicals. The major change in the last decade is a shift towards more physiologically relevant yet complex and sensitive cell models, like stem cells, and more recently, the shift to human induced pluripotent cells. Stem-cell technology has the potential to revolutionize drug discovery, making models available for primary screens, secondary pharmacology, safety pharmacology, metabolic profiling and toxicity evaluation. The overall aim of DropTech is the development of automated handling processes for stem cells with integrated readout methods, required for the use of stem cells in high-throughput assays such as the embryonic stem cell test (EST). DropTech will result on the one hand in a fully automated screening platform, usable by the industrial partners for reproducible and standardized high-throughput screening services and aggregate production. On the other hand a system that is directly exploitable for industrialization and marketing will be available to perform reliable and fast at least semi-automated screening approaches for customers. Therefore, the complete workflow of the EST, including stem cell expansion, embryoid body formation in hanging drops and transfer to 2D conditions will be automated using robotic and microfluidics systems. This will enable standardized, fast and efficient embryotoxicity screenings reducing the need for animal tests. DropTech will enable testing in a small- and medium-scaled budget accessible for SMEs and academia in the field of biotech and biomedicine. The DropTech platform will have therefore a significant impact on the development of new medication and therapies and will enable personalized medicine approaches as well as - in future - regenerative medicine. DropTech facilitate the use of cell models with highest biological relevance (human pluripotent stem cells) in their native conformation.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
  • /social sciences/sociology/governance/public services
  • /medical and health sciences/basic medicine/pharmacology and pharmacy

Call for proposal

FP7-HEALTH-2013-INNOVATION-2
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Address
Hansastrasse 27C
80686 Munchen
Germany
Activity type
Research Organisations
EU contribution
€ 2 015 949
Administrative Contact
Andrea Zeumann (Ms.)

Participants (3)

European ScreeningPort GmbH

Participation ended

Germany
EU contribution
€ 943 135
Address
Schnackenburgallee
22525 Hamburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mira Grättinger (Dr.)
ROSLIN CELLAB LIMITED
United Kingdom
EU contribution
€ 816 139
Address
Wallace Building Roslin Biocentre
EH25 9PP Roslin Midlothian
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Malcolm Bateman (Mr.)
ARTTIC
France
EU contribution
€ 276 096
Address
Rue Du Dessous Des Berges 58A
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Annette Ringwald (Ms.)